hydron;6-methoxy-N-[(1-prop-2-enylpyrrolidin-2-yl)methyl]-3H-benzotriazole-5-carboxamide;chloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 英文名称: hydron;6-methoxy-N-[(1-prop-2-enylpyrrolidin-2-yl)methyl]-3H-benzotriazole-5-carboxamide;chloride
• 化学式: C16H22ClN5O2
• 分子量: 351.8
• InChiKey: BRECEDGYMYXGNF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.77
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  83.1
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• METHODS AND COMPOSITIONS FOR TREATING INFECTION
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20150238473A1

  公开（公告）日：2015-08-27

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• Methods and compositions for treating infection
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US10004701B2

  公开（公告）日：2018-06-26

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
  申请人：Chase Pharmaceuticals Corporation

  公开号：US10307409B2

  公开（公告）日：2019-06-04

  A combination of a muscarinic cholinergic receptor agonist, a non-anticholinergic antiemetic agent and a non-selective, peripheral anticholinergic agent for the treatment of hypocholinergic disorders of the central nervous system.

  一种毒蕈碱胆碱能受体激动剂、一种非抗胆碱能止吐药和一种非选择性外周抗胆碱能药的复方制剂，用于治疗中枢神经系统的低胆碱能紊乱。
• Memantine combinations and use
  申请人：CHASE PHARMACEUTICALS CORPORATION

  公开号：US10548855B2

  公开（公告）日：2020-02-04

  A pharmaceutical combination of memantine and a non-anticholinergic antiemetic agent for the treatment of hypocholinergic disorders in further combination with high doses of donepezil and with solifenacin, and kits comprising said combination. A pharmaceutical combination of memantine and solifenacin for the treatment of hypocholinergic disorders, including Alzheimer type dementia, in further combination with high doses of donepezil, and kits comprising said combination.

  一种治疗低胆碱能紊乱的美金刚和非抗胆碱能止吐药的药物组合，进一步与大剂量多奈哌齐和索利芬那新组合，以及包含所述组合的试剂盒。一种美金刚和索利芬那新的药物组合，用于治疗低胆碱能疾病，包括阿尔茨海默型痴呆，进一步与大剂量多奈哌齐组合，以及包含所述组合的试剂盒。
• MUSCARINIC COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM
  申请人：Chase Pharmaceuticals Corporation

  公开号：EP3347011A1

  公开（公告）日：2018-07-18